India’s Pricing Authority Has New Chief, Again
India’s National Pharmaceutical Pricing Authority has a new chief, and pharma hopes that pricing policy outlook on the domestic market remains stable against the backdrop of a challenging operating environment globally.
You may also be interested in...
India has put in place a new panel to act as a 'recommending body' to the National Pharmaceutical Pricing Authority, raising questions about the pricing body’s autonomy and whether its role has been 'usurped'. The pharma industry claims a balanced pricing regime may emerge under the new system but doesn’t rule out inter-department conflicts in the government.
Cipla sees an incremental revenue opportunity of up to $500m for its US franchise by fiscal 2025 and expects to propel growth with strong execution of its complex generics pipeline. The company is also beginning to “lay the blueprint” in China and Brazil, it said at the J.P. Morgan Healthcare Conference.
The new leader at Boehringer Ingelheim India has a full plate and significant expectations riding on her to sustain momentum at one of the fastest-growing foreign pharma firms in the country.